J Glob Health. 2012 June; 2(1): 010403. | PMCID: PMC3484758 |
Copyright © 2012 by the Journal of Global Health. All rights reserved.
Setting research priorities to reduce global mortality from preterm birth and low birth weight by 2015
Rajiv Bahl,1*† Jose Martines,1*† Nita Bhandari,2 Zrinka Biloglav,3 Karen Edmond,4 Sharad Iyengar,5 Michael Kramer,6 Joy E. Lawn,7 D. S. Manandhar,8 Rintaro Mori,9 Kathleen M. Rasmussen,10 H. P. S. Sachdev,11 Nalini Singhal,12 Mark Tomlinson,13 Cesar Victora,14 Anthony F. Williams,15 Kit Yee Chan,16* and Igor Rudan17*
1Department of Child and Adolescent Health and Development, World Health Organization, Geneva, Switzerland
2Centre for Health Research and Development, Society for Applied Studies, New Delhi, India
3Andrija Štampar School of Public Health, School of Medicine, University of Zagreb, Croatia
4London School of Hygiene and Tropical Medicine, London, UK
5Action Research & Training for Health, Udaipur, India
6Departments of Pediatrics and of Epidemiology and Biostatistics, McGill University Faculty of Medicine, Montreal, Canada
7Saving Newborn Lives – Save the Children, Cape Town, South Africa.
8Mother and Infant Research Activities, Kathmandu, Nepal
9Department of Global Health Policy, Graduate School of Medicine, the University of Tokyo, Japan
10Division of Nutritional Sciences, Cornell University, Ithaca, NY, USA
11Sitaram Bhartia Institute of Science and Research, New Delhi, India
12Department of Pediatrics, University of Calgary, Canada
13Department of Psychology, Stellenbosch University, Stellenbosch, South Africa
14Federal University of Pelotas, Pelotas, Brazil
15St George's, University of London, London, UK
16Nossal Institute for Global Health, Melbourne University, Melbourne, Australia
17Centre for Population Health Sciences, The University of Edinburgh Medical School, Edinburgh, Scotland, UK
*Equal authors’ contributions
†Staff of the World Health Organization
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Investment in global health research today would benefit from consensus regarding the context, appropriate investment strategies, and co-ordination to achieve significant reduction of the disease burden in the foreseeable future. The present exercise was designed to assist investors and policy makers in making more informed choices on their investments in health research on PB/LBW by making apparent the risks and potential benefits associated with investments in a broad spectrum of health research options. The expected “profit” from investments is associated with generating new knowledge that can be translated into development of new (or improvement of existing) interventions, which are effective, deliverable, affordable, and can reduce the existing burden of disease and disability in an equitable way. The risk is associated with research that is not likely to be answerable, or that develops products unlikely to be effective, deliverable, affordable, or sustainable by those who need them most. Investors' preference for high-risk investment in health research is particularly questionable when it is occurring in a context that requires urgent progress, such as PB/LBW mortality. The focus on complex challenges of implementation (ie, improving health systems, training health workers including poorly educated village health workers, improving drug supply and delivery at community level, etc.), highlighted in this exercise, was reflected in many research questions being ranked near the top of the list of overall priorities.
The context for this exercise was set within the MDG4, requiring an urgent and rapid progress in mortality reduction from low birth weight, rather than identifying long-term strategic solutions of the greatest potential. In a short-term context, the health policy and systems research to improve access and coverage by the existing interventions, coupled with further research to improve effectiveness, deliverability and acceptance of existing interventions, and epidemiological research to address the key gaps in knowledge, were all highlighted as research priorities.
Although the advantages of the CHNRI methodology represent a serious attempt to deal with many issues inherent to a highly complex process of research investment priority setting, there are still concerns over the validity of the CHNRI approach and related biases. One of them is related to the fact that many possible good ideas (“research investment options”) may not have been included in the initial list of research options that was scored by the experts, and to the potential bias toward items that get the greatest press. Another concern over the CHNRI process is that its end product represents a possibly biased opinion of a very limited group of involved people. In theory, a chosen group of experts can have biased views in comparison to any other potential groups of experts. Those limitations are described and discussed in greater detail in the Online Supplementary Document
(Online Supplementary Document) (table w1).
The implementation of the CHNRI methodology showed that, within the context of MDG4, a better balance should be achieved between specific domains of health research. Along with continuing strategic long-term investments in new interventions, which represent high-risk high-profit strategies, the CHNRI process suggested that more attention should be given to health policy research, health systems research, operations research, and research that addresses political, economic, social, cultural, behavioral, and infrastructure issues surrounding the problem of child mortality from PB/LBW. These domains of health research are rarely recognized as attractive by investors in health research because their results are unlikely to grab the newspaper headlines, get published in journals with high impact factors, or lead to patents and commercial products. Yet, they can generate new knowledge that can be very helpful in achieving real progress in disease burden reduction. The identified priorities are also in good agreement with the research supported by WHO’s MNCAHD Department at present. They emphasize the evaluation of existing interventions and the development and testing of new delivery approaches for existing interventions. They also highlight the value of research on preventive measures, with research on new interventions being downplayed within the short-term context.